An interventional study of THS1 (TP18 variant 1) and THS2 (TP18 variant 2) in Smoking, sponsored by Philip Morris Products S.A.. Active, not recruiting at 1 site in United Kingdom. Open to participants aged 21 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by Philip Morris Products S.A. (part of Philip Morris International) · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Smoking by Philip Morris International — none open to participants now, 2 under way, none of them phase 3. Smoking · Philip Morris International.
Among the 36 studies in Smoking by Philip Morris International, this one is the 13th largest by enrollment of the 32 interventional ones that give a count, is the only one that started in 2026, is one of 31 with no phase, and was the 36th registered.
1,516 studies on the registry are indexed under Smoking; 196 are open to participants now.
Browse Smoking studies →None of the 36 studies in Smoking by Philip Morris International is open now. The open studies under Smoking, anywhere →
Of the 145 Smoking studies recruiting now, 76 (52%) set no upper age limit and 51 (35%) stop at 75 or younger; 3 take children under 18; 69 take healthy volunteers.
This study: 21 Years to 65 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2026.
This study's enrollment of 108 is close to the median of 116 across 1,167 interventional studies indexed under Smoking.
Median enrollment 87 across the 32 interventional studies, 1,097 across the 4 observational. Of the 33 that completed or were terminated, 26 (79%) have results posted.
This tab as a report to print or save as PDF → With an account.
This study is registered under Philip Morris Products S.A., one of the names counted as Philip Morris International. Under that name alone:
Philip Morris Products S.A. is the lead sponsor of 49 studies on the registry; none are open to participants now.
1 of the studies in Smoking by Philip Morris International that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07108166Philip Morris Products S.A.Symptoms and Functions in Patients With COPD and Chronic Bronchitis Switching From CIG to THS | 2027-02 |
Add it to your calendar (.ics) → With an account.
Among the 36 studies in Smoking by Philip Morris International, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, controlled, open-label, 6 parallel arms study to assess reduced exposure of biomarkers of exposure (BoE) of selected HPHC in smokers switching to TP18 (a prototype heated tobacco device) or THS relative to smokers who continue smoking CIG after 5 days of confinement period, followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
This randomized, controlled, open-label study comprises six parallel arms and is designed to evaluate reductions in biomarkers of exposure (BoE) to selected HPHCs in adult smokers switching toTP18 (a prototype heated tobacco device with four variants: THS1, THS2, THS3, THS4) or THS5 relative to smokers who continue smoking CIG after 5 days of confinement period followed by 2 days of pharmacokinetic (PK) period of single use of THS/TP18 and CIG, and followed by an ambulatory period.
During the 5-day confinement period, participants will be randomized to use only their assigned product and will operate their assigned devices (THS1, THS2, THS3, THS4, or THS5) with their corresponding sticks or continue smoking CIG ad libitum (6 arms in total).
In the subsequent 2-day PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. Participants randomized to the CIG arm at Baseline will not participate in this period.
During the ambulatory period, participants randomized to one of the TP18 versions at Baseline will be free to choose and use any TP18 variant at any time, ad libitum. Participants randomized at Baseline to TP18 will continue using THS ad libitum. Participants randomized to the CIG arm will only be smoking cigarettes, ad libitum.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
During the confinement period, participants will use only their assigned product THS 1 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.
Other: THS1 (TP18 variant 1)
During the confinement period, participants will use only their assigned product THS 2 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.
Other: THS2 (TP18 variant 2)
During the confinement period, participants will use only their assigned product THS 3 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.
Other: THS3 (TP18 variant 3)
During the confinement period, participants will use only their assigned product THS 4 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they may choose any variant (THS1, THS2, THS3, or THS4) at any time, ad libitum.
Other: THS4 (TP18 variant 4)
During the confinement period, participants will use only their assigned product THS 5 (with the corresponding sticks) ad libitum. During the PK period, they will complete a four-way single-product crossover using THS/TP18 and CIG, according to randomized product sequences. During the ambulatory period, they will be continue to use THS5 ad libitum.
Other: THS5 (THS 3.0 reference device)
During the confinement period, participants will use only their usual brand of commercially available CIG ad libitum. This arm will not participate in the PK period and will move directly to the ambulatory period. During the ambulatory period, participants will smoke only cigarettes, ad libitum.
Other: CIG (Cigarette)
TP18 prototype variant "1" (THS1) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.
TP18 prototype variant "2" (THS2) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.
TP18 prototype variant "3" (THS3) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.
TP18 prototype variant "4" (THS4) and associated tobacco sticks. The Sponsor will supply two types of sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants can choose either or both variants.
THS 3.0 device (reference) and the corresponding tobacco sticks will be provided by the Sponsor. There are two variants of the sticks: regular (tobacco flavor) and non-characterizing menthol flavor. Participants may choose either variant or both.
Current cigarette smokers will use their usual brand of commercially available CIG.
3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (confinement period)
Concentrations of 3-HPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
2-cyanoethyl mercapturic acid N-acetyl-S-(2-cyanoethyl)-L-cysteine (2-CyEMA) in Urine (confinement period)
Concentrations of 2-CyEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (confinement period)
Concentrations of MHBMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Total N-nitrosonornicotine (total NNN) in Urine (confinement period)
Concentrations of total NNN measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (total NNAL) in Urine (confinement period)
Concentrations of total NNAL measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Carboxyhemoglobin (COHb) in Blood (confinement period)
Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide.
Time frame: Measured from Day -1 to Day 5.
S-phenylmercapturic acid (S-PMA) in Urine (confinement period)
Concentrations of S-PMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
2-hydroxyethylmercapturic acid (2-HEMA) in Urine (confinement period)
Concentrations of 2-HEMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (confinement period)
Concentrations of 3-HMPMA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (confinement period)
Concentrations of 3-OH-B\[a\]P measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
4-aminobiphenyl (4-ABP) in Urine (confinement period)
Concentrations of 4-ABP measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
2-aminonaphtalene (2-NA) in Urine (confinement period)
Concentrations of 2-NA measured in 24-hour urine and expressed as concentration adjusted for creatinine.
Time frame: Measured from Day -1 to Day 5.
Plasma nicotine concentrations [C0h] to [C6h] (pharmacokinetic period)
To measure the background-corrected plasma nicotine concentrations (C0h) to (C12h)
Time frame: Measured from Day 6 to Day 7.
Maximum plasma nicotine concentration [Cmax] (pharmacokinetic period)
To measure the background-corrected maximum plasma nicotine concentration \[Cmax\]
Time frame: Measured from Day 6 to Day 7.
Area under the plasma nicotine concentration-time curve (pharmacokinetic period)
To measure the area under the background-corrected plasma nicotine concentration-time curve (AUC) from the start of product use (T0) to the timepoint of last quantifiable concentration \[AUC0-last\] and extrapolated to infinity \[AUC0-infinity\]
Time frame: Measured from Day 6 to Day 7.
Maximum concentration [Tmax] (pharmacokinetic period)
To measure the time to the background-corrected maximum concentration \[Tmax\]
Time frame: Measured from Day 6 to Day 7.
3-hydroxypropyl mercapturic acid (3-HPMA) in Urine (ambulatory period)
Concentrations of 3-HPMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
2-cyanoethyl mercapturic acid N-acetyl-S-(2- cyanoethyl)-L-cysteine (2-CyEMA) in Urine (ambulatory period)
Concentrations of 2-CyEMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Monohydroxybutenyl mercapturic acid (MHBMA) in Urine (ambulatory period)
Concentrations of MHBMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Total N-nitrosonornicotine (total NNN) in Urine (ambulatory period)
Concentrations of total NNN measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Total 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol (ambulatory period)
Concentrations of total NNAL measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Carboxyhemoglobin (COHb) in Blood (ambulatory period)
Carboxyhemoglobin (COHb) is assayed from whole blood and expressed as percentage of the total hemoglobin saturated with carbon monoxide.
Time frame: Measured on Day 30 and Day 60.
S-phenylmercapturic acid (S-PMA) in Urine (ambulatory period)
Concentrations of S-PMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
2-hydroxyethylmercapturic acid (2-HEMA) in Urine (ambulatory period)
Concentrations of 2-HEMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
3-hydroxy-1-methylpropylmercapturic acid (3-HMPMA) in Urine (ambulatory period)
Concentrations of 3-HMPMA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Total 3-hydroxybenzo(a)pyrene (3-OH-B[a]P) in Urine (ambulatory period)
Concentrations of 3-OH-B\[a\]P measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
4-aminobiphenyl (4-ABP) in Urine (ambulatory period)
Concentrations of 4-ABP measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
2-aminonaphtalene (2-NA) in Urine (ambulatory period)
Concentrations of 2-NA measured in spot urine and expressed as concentration adjusted for creatinine.
Time frame: Measured on Day 30 and Day 60.
Ran from Feb 2026 to primary completion in Jul 2026, 5 months.
Of 56 industry-sponsored interventional studies with no phase under Smoking, half reached primary completion within 3 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 6. This study's 5 months is above that.
Counting every sponsor, half of 461 studies reached it within 23 months; a quarter within 8 and three quarters within 40.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.